<div id="readability-page-1"><p>Bank of America Securities analyst Michael Ryskin reiterated a Hold rating on 10x Genomics today and set a price target of $18.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Ryskin is a 4-star analyst with an average return of <span>4.2%</span> and a 56.40% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Illumina, Thermo Fisher, and Elanco Animal Health.</p> <p>In addition to Bank of America Securities, 10x Genomics also received a Hold from Citi’s Patrick B Donnelly in a report issued on December 11. However, today, Barclays maintained a Buy rating on 10x Genomics (NASDAQ: TXG).</p></div>

<p>Bank of America Securities analyst Michael Ryskin reaffirmed a Hold rating on 10x Genomics with a price target of $18.00. Ryskin, a 4-star analyst, focuses on the Healthcare sector. Additionally, Citi's Patrick B Donnelly also issued a Hold rating, while Barclays maintained a Buy rating on 10x Genomics.</p>

Bank of America Securities Reaffirms Their Hold Rating on 10x Genomics (TXG)